Anti-inflammatory, antioxidant, and gaso-protective mechanism of 3α-hydroxymasticadienoic acid and diligustilide combination on indomethacin gastric damage

• Published in: Naunyn-Schmiedeberg's archives of pharmacology 2020-08, Vol.393 (8), p.1501-1513
• Main Authors: Pineda-Peña, Elizabeth Arlen, Orona-Ortiz, Alejandra, Velázquez-Moyado, Josué Arturo, Tavares-Carvalho, José Carlos, Chávez-Piña, Aracely Evangelina, Balderas-López, José Luis, Navarrete, Andrés
• Format: Article
• Language: English
• Subjects: Animal models; Antioxidants; Biomedical and Life Sciences; Biomedicine; Enzymatic activity; Hydrogen sulfide; Indomethacin; Inflammation; Mucosa; Neurosciences; Original Article; Pharmacology/Toxicology; Prostaglandin E2; Rodents; Tumor necrosis factor-α; Ulcers
• ISSN: 0028-1298; 1432-1912
• DOI: 10.1007/s00210-020-01857-7

The co-administration of 3α-hydroxymasticadienoic acid (3α-OH MDA) and diligustilide (DLG) generates a synergist gastroprotective effect on indomethacin-induced gastric damage. However, the related protective activities of the compounds alone (or in combination) remain unclear. In the present study, we evaluated the anti-inflammatory and antioxidative activities, as well as the potential modulation of important gasotransmitters of each compound individually and in combination using the indomethacin-induced gastric damage model. Male Wistar rats were treated orally with the 3α-OH MDA, DLG, or their combination (at a fixed ratio of 1:1, 1:3, and 3:1) 30 min before the generation of gastric mucosal lesions with indomethacin (30 mg/kg, p.o.). Three hours later, the gastric injury (mm 2 ) was determined. Results from these experiments indicate, in addition to maintaining basal levels of PGE 2 , the gastroprotective effect of the pre-treatment with 3α-OH MDA (70%), DLG (81%), and their combination (72%) which was accompanied by significant decreases in leukocyte recruitment, as well as decreases in TNF-α and LTB 4 gastric levels ( p